BACKGROUND: Gastrointestinal (GI) malignancies represent a heterogeneous group of diseases. Traditional tumor markers, though part of standard-of-care, lack sensitivity and specificity. Tumor-informed circulating tumor DNA (ctDNA) assay-based molecular residual disease assessment as well as recurrence and treatment response monitoring can serve as a robust tool in patients with wide range of GI malignancies and ethnicities. METHODS: A personalized, tumor-informed multiplex PCR-NGS assay (SignateraTM) was used for the detection and quantification of ctDNA in 258 plasma samples from 198 patients with GI cancers at two institutions. Serial time- points were collected on a subset of patients (n=64) to monitor their ctDNA levels in response to treatment. Chi-square test was used to compare ctDNA-positivity rates in different cohorts. RESULTS: The study included stage I-IV patients with a median age of 62 years (61% females and 49% ethnic minorities); 92% had surgical resection, 83% received systemic treatment. ctDNA-positivity was significantly associated with advanced stage (P=0.004), and presence/extent of metastases (P<0.00003). Serial time-point analysis showed that 22% (14/64) patients cleared ctDNA following treatment. ctDNA was detected in all patients who recurred (4/4; 100% sensitivity). CONCLUSIONS: Serial monitoring of ctDNA using a tumor-informed ctDNA assay can be prognostic and predictive in advanced GI malignancies in adjuvant setting. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Gastrointestinal (GI) malignancies represent a heterogeneous group of diseases. Traditional tumor markers, though part of standard-of-care, lack sensitivity and specificity. Tumor-informed circulating tumor DNA (ctDNA) assay-based molecular residual disease assessment as well as recurrence and treatment response monitoring can serve as a robust tool in patients with wide range of GI malignancies and ethnicities. METHODS: A personalized, tumor-informed multiplex PCR-NGS assay (SignateraTM) was used for the detection and quantification of ctDNA in 258 plasma samples from 198 patients with GI cancers at two institutions. Serial time- points were collected on a subset of patients (n=64) to monitor their ctDNA levels in response to treatment. Chi-square test was used to compare ctDNA-positivity rates in different cohorts. RESULTS: The study included stage I-IV patients with a median age of 62 years (61% females and 49% ethnic minorities); 92% had surgical resection, 83% received systemic treatment. ctDNA-positivity was significantly associated with advanced stage (P=0.004), and presence/extent of metastases (P<0.00003). Serial time-point analysis showed that 22% (14/64) patients cleared ctDNA following treatment. ctDNA was detected in all patients who recurred (4/4; 100% sensitivity). CONCLUSIONS: Serial monitoring of ctDNA using a tumor-informed ctDNA assay can be prognostic and predictive in advanced GI malignancies in adjuvant setting. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Mustafa A Arain; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Linda Farkas; Ignacio Garrido-Laguna; Jean L Grem; Andrew Gunn; J Randolph Hecht; Sarah Hoffe; Joleen Hubbard; Steven Hunt; Kimberly L Johung; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Eric D Miller; Mary F Mulcahy; Steven Nurkin; Michael J Overman; Aparna Parikh; Hitendra Patel; Katrina Pedersen; Leonard Saltz; Charles Schneider; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Kristina M Gregory; Lisa A Gurski Journal: J Natl Compr Canc Netw Date: 2021-03-02 Impact factor: 11.908
Authors: J Tie; I Kinde; Y Wang; H L Wong; J Roebert; M Christie; M Tacey; R Wong; M Singh; C S Karapetis; J Desai; B Tran; R L Strausberg; L A Diaz; N Papadopoulos; K W Kinzler; B Vogelstein; P Gibbs Journal: Ann Oncol Date: 2015-04-07 Impact factor: 32.976
Authors: Alok A Khorana; Shannon E McKernin; Jordan Berlin; Theodore S Hong; Anirban Maitra; Cassadie Moravek; Matthew Mumber; Richard Schulick; Herbert J Zeh; Matthew H G Katz Journal: J Clin Oncol Date: 2019-06-10 Impact factor: 44.544
Authors: Christopher Lieu; Erin B Kennedy; Emily Bergsland; Jordan Berlin; Thomas J George; Sharlene Gill; Philip J Gold; Alex Hantel; Lee Jones; Najjia Mahmoud; Jeffrey Meyerhardt; Arden M Morris; Erika Ruíz-García; Y Nancy You; Nancy Baxter Journal: J Clin Oncol Date: 2019-04-15 Impact factor: 44.544
Authors: Jeanne Tie; Yuxuan Wang; Cristian Tomasetti; Lu Li; Simeon Springer; Isaac Kinde; Natalie Silliman; Mark Tacey; Hui-Li Wong; Michael Christie; Suzanne Kosmider; Iain Skinner; Rachel Wong; Malcolm Steel; Ben Tran; Jayesh Desai; Ian Jones; Andrew Haydon; Theresa Hayes; Tim J Price; Robert L Strausberg; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs Journal: Sci Transl Med Date: 2016-07-06 Impact factor: 17.956
Authors: Christopher Abbosh; Nicolai J Birkbak; Gareth A Wilson; Mariam Jamal-Hanjani; Tudor Constantin; Raheleh Salari; John Le Quesne; David A Moore; Selvaraju Veeriah; Rachel Rosenthal; Teresa Marafioti; Eser Kirkizlar; Thomas B K Watkins; Nicholas McGranahan; Sophia Ward; Luke Martinson; Joan Riley; Francesco Fraioli; Maise Al Bakir; Eva Grönroos; Francisco Zambrana; Raymondo Endozo; Wenya Linda Bi; Fiona M Fennessy; Nicole Sponer; Diana Johnson; Joanne Laycock; Seema Shafi; Justyna Czyzewska-Khan; Andrew Rowan; Tim Chambers; Nik Matthews; Samra Turajlic; Crispin Hiley; Siow Ming Lee; Martin D Forster; Tanya Ahmad; Mary Falzon; Elaine Borg; David Lawrence; Martin Hayward; Shyam Kolvekar; Nikolaos Panagiotopoulos; Sam M Janes; Ricky Thakrar; Asia Ahmed; Fiona Blackhall; Yvonne Summers; Dina Hafez; Ashwini Naik; Apratim Ganguly; Stephanie Kareht; Rajesh Shah; Leena Joseph; Anne Marie Quinn; Phil A Crosbie; Babu Naidu; Gary Middleton; Gerald Langman; Simon Trotter; Marianne Nicolson; Hardy Remmen; Keith Kerr; Mahendran Chetty; Lesley Gomersall; Dean A Fennell; Apostolos Nakas; Sridhar Rathinam; Girija Anand; Sajid Khan; Peter Russell; Veni Ezhil; Babikir Ismail; Melanie Irvin-Sellers; Vineet Prakash; Jason F Lester; Malgorzata Kornaszewska; Richard Attanoos; Haydn Adams; Helen Davies; Dahmane Oukrif; Ayse U Akarca; John A Hartley; Helen L Lowe; Sara Lock; Natasha Iles; Harriet Bell; Yenting Ngai; Greg Elgar; Zoltan Szallasi; Roland F Schwarz; Javier Herrero; Aengus Stewart; Sergio A Quezada; Karl S Peggs; Peter Van Loo; Caroline Dive; C Jimmy Lin; Matthew Rabinowitz; Hugo J W L Aerts; Allan Hackshaw; Jacqui A Shaw; Bernhard G Zimmermann; Charles Swanton Journal: Nature Date: 2017-04-26 Impact factor: 49.962